Abstract: Provided are an ozone catalytic elimination device and a plasma beauty instrument including the ozone catalytic elimination device. The ozone catalytic elimination device includes an air pumping device, a catalytic device, a heating device, and a cooling device. An air inlet end of the air pumping device is used for communicating with an ionization cavity of the plasma beauty instrument, an air outlet end of the air pumping device communicates with the catalytic device, and ozone generated by the ionization cavity can be pumped to the catalytic device by the air pumping device. The catalytic device is configured to catalyze the ozone into oxygen, the heating device can be configured to heat the ozone, the cooling device communicates with the interior of the catalytic device, and the cooling device can be configured to cool the oxygen.

Abstract: Embodiments of the present invention relate to use of a GP73 inhibitor in preparation of a drug for treating diabetes. In the embodiments of the present invention, the inventor finds that GP73 plays a key role in blood glucose regulation, and in particular, finds that soluble GP73 can specifically bind to glucagon to form a complex, enhances the blood glucose-rising function and gluconeogenesis function of glucagon and prolongs the half-life of glucagon; and finds soluble GP73 can activate the glucose production in liver and/or kidney and a gluconeogenesis signaling pathway in a glucagon-independent manner. Based on the blood glucose regulation effect of the GP73 described above, the inventor also proves through animal experiments: the GP73 inhibitor can reduce the blood glucose level and glycated hemoglobin level of diabetic mice and have a protective effect on islet ? cells, and thereby having the effect of treating diabetes.